University of Kentucky Sanders-Brown Center on Aging
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jicha, Gregory
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
Jones, Keisha
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
NCT05250908: INTIBIA Pivotal Study

Active, not recruiting
N/A
208
Europe, US
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Coloplast A/S
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
06/25
06/26

Download Options